Andere Sprachen Medigene AG

Aktien

A1X3W0

DE000A1X3W00

MDG1

Realtime-Estimate Tradegate Andere Börsenplätze 15:30:00 18.04.2024			% 5 Tage	% 1. Jan.
1.925 ^EUR	+4.34%		-12.91%	+21.64%

08.04.	Medigene AG präsentiert günstiges Sicherheitsprofil von TCR-T-Zellen mit kostimulatorischem Switch-Protein auf der AACR-Jahrestagung 2024	CI
04.04.	Medigene erhält europäisches Patent für T-Zell-Rezeptor-Technologie	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Medigene to Present at Upcoming Scientific Conferences	17.04.
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	08.04.
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	08.04.
Medigene Gets European Patent for T-Cell Receptor Technology	04.04.
Medigene AG Secures European Patent for its iM-TCR Technology	04.04.
Medigene AG Secures European Patent for Its iM-TCR Technology	04.04.
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Medigene : Statement on Corporate Governance 2023	28.03.
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update	28.03.
Medigene Ag Provides Earnings Guidance for 2024	28.03.
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	19.03.
Medigene AG to report full year 2023 financial results on March 28, 2024	18.03.
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting	06.03.
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo	04.03.
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo	04.03.
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	04.03.
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies	29.02.
Medigene to Present at Upcoming Conferences	19.02.
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors	12.02.
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	12.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Medigene AG

Aktien

A1X3W0

DE000A1X3W00

MDG1

Andere Sprachen

Filter